Medicus Pharma price target raised to $27 from $14 at D. Boral Capital

D. Boral Capital analyst Jason Kolbert raised the firm’s price target on Medicus Pharma (MDCX) to $27 from $14 and keeps a Buy rating on the shares after the company signed a binding letter of intent to acquire Antev. This acquisition adds “significant strategic value” by bringing in Teverelix, a next-generation GnRH antagonist with strong clinical rationale and late-stage readiness, the analyst tells investors in a research note. The firm says Teverelix addresses two large, underserved markets – acute urinary retention recurrence prevention and advanced prostate cancer in patients with high cardiovascular risk. D. Boral views the transaction as a “savvy, de-risked pipeline expansion that materially enhances Medicus’ near-commercial portfolio and positions the company for accelerated value creation.”